参考文献/References:
[1]师晓艳,雷侠.宫颈液基细胞学检查与高危型HPV检测用于宫颈癌前病变并发感染早期筛查的对比研究[J].中国性科学,2017,26(1):33-35.[2]赵青莲,张帅,刘鑫鑫,等.中晚期宫颈癌患者应用调强适形放疗联合化疗的相关临床研究[J].中国医师杂志,2018,20(2):243-246.[3]Luvero D,Plotti F,Lopez S,et al.Antiangiogenics and immunotherapies in cervical cancer: an update and future’s view[J].Medical Oncology,2017,34(6):115.[4]杜欣欣,杨昊,张慧娟,等.子宫颈癌根治性放疗中不同体外照射技术联合三维近距离放疗的剂量学研究及临床观察[J].中华妇产科杂志,2017,52(10):679-686.[5]张维帅,杨东明,贺蕾,等.三维适形放疗与容积调强放疗治疗局部晚期宫颈癌比较研究[J].临床军医杂志,2019,47(3):287-289.[6]王巧娥,胡小刚,许海.调强放疗联合腔内近距离放疗对晚期宫颈癌患者肿瘤标志物及雌孕激素的影响[J].中国性科学,2018,27(9):32-35.[7]周琦,吴小华,刘继红,等.宫颈癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(6):613-622.[8]Lei C,Ma S,Huang M,et al.Long-Term Survival and Late Toxicity Associated With Pelvic Intensity Modulated Radiation Therapy (IMRT) for Cervical Cancer Involving CT-Based Positive Lymph Nodes[J].Frontiers in Oncology,2019,9:520.[9]乔志安.调强放疗与三维适形放疗联合腔内后装放疗治疗中晚期宫颈癌的效果研究[J].中国医药导刊,2017,19(5):474-475.[10]杨江华,张丹丹,高琴,等.同步放化疗与序贯放化疗对宫颈癌中晚期患者血液毒性以及肿瘤标志物的影响[J].实用癌症杂志,2017,32(7):1082-1084,1090.[11]Pereira E,Cooper HH,Zelaya PG,et al.Concurrent chemoradiation versus radiotherapy alone for the treatment of locally advanced cervical cancer in a low-resource setting[J].Gynecologic Oncology Reports,2017,19:50-52.[12]侯洁,赵田勇,鲍沁露.紫杉醇联合卡铂化疗同期调强适形放疗在老年晚期宫颈癌患者中的应用[J].中华老年医学杂志,2021,40(1):92-95.[13]李金砖,陈绍俊.顺铂与奈达铂同步放化疗治疗宫颈癌的疗效与安全性比较[J].广西医学,2019,41(9):1078-1081.[14]刘淑荣,廖革望.局部晚期宫颈癌化疗联合放疗最佳模式探讨[J].中华肿瘤防治杂志,2017,24(3):196-200.[15]Apte RS,Chen DS,Ferrara N.VEGF in Signaling and Disease: Beyond Discovery and Development[J].Cell,2019,176(6):1248-1264.[16]张卫霞,杨婷,刘娟妮,等.贝伐单抗联合多西他赛治疗晚期宫颈癌的临床疗效及安全性观察[J].药物评价研究,2017,40(1):100-103.[17]Rahmani AH,Yousif AA,Alsahli MA,et al.Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma[J].Open Access Macedonian Journal of Medical Sciences,2018,6(2):263-268.[18]Tewari KS,Sill MW,Penson RT,et al.Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)[J].Lancet,2017,390(10103):1654-1663.[19]Cohen PA,Jhingran A,Oaknin A,et al.Cervical cancer[J].The Lancet,2019,393(10167):169-182.[20]Sugiyama T,Mizuno M,Aoki Y,et al.A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer[J].Jpn J Clin Oncol,2017,47(1):39-46.[21]杨华,魏丽春,张莹,等.联合贝伐珠单抗新辅助化疗＋同步放化疗治疗局部晚期巨块型宫颈癌的初步临床研究[J].中华放射肿瘤学杂志,2021,30(4):372-375.[22]Gyawali B,Iddawela M.Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries[J].J Glob Oncol,2017,3(2):93-97.[23]Borcoman E,Tourneau CL.Pembrolizumab in cervical cancer: latest evidence and clinical usefulness[J].Therapeutic Advances in Medical Oncology,2017,9(6):431-439.[24]Li S,Ma YM,Zheng PS,et al.GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2[J].Journal of Experimental & Clinical Cancer Research,2018,37(1):80.[25]Liu Y,An Q,Zhao X.A pan-HER-targeted approach for recurrent or latestage cervical cancer therapy: mechanisms, recent advances, and clinical prospects[J].Eur Rev Med Pharmacol Sci,2020,24(8):4123-4131.[26]田淑贞,王运贤,田梦圆,等.尼妥珠单抗联合放化疗治疗耐药性宫颈癌动物实验研究[J].中华肿瘤防治杂志,2017,24(18):1284-1289.[27]李璐,黄建鸣,冯梅,等.放射诱导的EGFR核转位阻断可增加人宫颈癌细胞放射敏感度[J].肿瘤防治研究,2020,47(1):25-31.[28]Pignata S,Scambia G,Lorusso D,et al.The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel,in advanced or recurrent cervical cancer[J].Gynecol Oncol,2019,153(3):535-540.[29]丁燕,司天斌,王雨村,等.细胞毒性T细胞、巨噬细胞和调节性T细胞在复发性宫颈癌患者中的免疫特征分析[J].免疫学杂志,2020,36(7):617-622.[30]王晶,佟秀琴.程序性死亡受体1配体、拓扑异构酶Ⅱα及p16蛋白在子宫颈癌中的表达及其意义[J].肿瘤研究与临床,2017,29(4):235-240.[31]彭瑾,付梦迪,张溪,等.PD-1单抗影响复发性宫颈癌后线化疗1例报道[J].现代妇产科进展,2021,30(10):799-800.[32]Naumann RW,Hollebecque A,Meyer T,et al.Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase Ⅰ/ⅡCheckMate 358 Trial[J].J Clin Oncol,2019,37(31):2825-2834.[33]Loi S,Adams S,Schmid P,et al.LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086[J].Annals of Oncology,2017,28(5):608.[34]Marco D,Julie WK,Rikke A,et al.PD-1+Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer[J].Clinical Cancer Research,2017,23(19):5779-5788.
相似文献/References:
[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息官方网站,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Medical Information,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息官方网站,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Medical Information,2018,31(15):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[3]蔡亚磊,邓思雨,杨 健.宫颈癌放疗增敏的研究现状[J].医学信息官方网站,2022,35(09):65.[doi:10.3969/j.issn.1006-1959.2022.09.016]
CAI Ya-lei,DENG Si-yu,YANG Jian.Research Status of Radiotherapy Sensitization for Cervical Cancer[J].Medical Information,2022,35(15):65.[doi:10.3969/j.issn.1006-1959.2022.09.016]
[4]车 莹.HPV感染与宫颈病变相关性的研究[J].医学信息官方网站,2022,35(09):84.[doi:10.3969/j.issn.1006-1959.2022.09.021]
CHE Ying.Study on the Correlation Between HPV Infection and Cervical Lesions[J].Medical Information,2022,35(15):84.[doi:10.3969/j.issn.1006-1959.2022.09.021]
[5]曹 亮,郝 朋,李阳明,等.宫颈癌所致输尿管梗阻患者输尿管支架置入成功率影响因素的Meta分析[J].医学信息官方网站,2022,35(09):124.[doi:10.3969/j.issn.1006-1959.2022.09.031]
CAO Liang,HAO Peng,LI Yang-ming,et al.Meta Analysis of Factors Influencing Success Rate of Ureteral Stent Implantation in Patients with Ureteral Obstruction Caused by Cervical Cancer[J].Medical Information,2022,35(15):124.[doi:10.3969/j.issn.1006-1959.2022.09.031]
[6]覃念群,刘 楷,米镜霖,等.基于生物信息学分析筛选与宫颈癌预后相关的关键基因[J].医学信息官方网站,2022,35(10):8.[doi:10.3969/j.issn.1006-1959.2022.10.002]
QIN Nian-qun,LIU Kai,MI Jing-lin,et al.Screening Key Genes Related to the Prognosis of Cervical Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(15):8.[doi:10.3969/j.issn.1006-1959.2022.10.002]
[7]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息官方网站,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Medical Information,2018,31(15):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[8]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息官方网站,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Medical Information,2018,31(15):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[9]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息官方网站,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Medical Information,2018,31(15):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[10]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息官方网站,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Medical Information,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]